Investors, including the New York City and State pension funds and the California State Teacher’s Retirement System, are urging shareholders to vote against Mylan (NSDQ:MYL) chairman Robert Coury and 5 other board members at the company’s upcoming annual meeting.
Coury was compensated with more than $97 million last year and some investors aren’t happy about it. The pensions funds are major institutional shareholders – together, they control 4.3 million shares of the EpiPen-maker.
Get the full story at our sister site, Drug Delivery Business News.
The post Mylan board faces pressure from pension funds appeared first on MassDevice.